Drug Approval | March 27, 2024
Ultomiris approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
Combination shows consistent benefit across prespecified post-progression outcomes
AbCellera will receive an upfront payment and is eligible to receive additional milestone payments
Sadhana Nitro Chem's plant is the second plant in the world to manufacture pAP from Nitrobenzene
Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months
PLI scheme envisages manufacturing of 41 Bulk Drugs with a total outlay of Rs. 6,940 cr. during the tenure of the scheme from 2020-21 to 2029-30
Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant
GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023
The company has received five final approvals
KBR will provide outreach, education and data analytics to support critical neuroscience research for the prevention and treatment of military members with CTE
Subscribe To Our Newsletter & Stay Updated
